Founder/CSO
BrainChild Bio, Inc.
BrainChild Bio is a clinical-stage biotechnology company developing CAR-T cell therapies for central nervous system tumors, prioritizing pediatric brain cancers like DIPG. Its platform delivers engineered cells directly into the cerebroventricular space, bypassing the blood-brain barrier, and uses multiplexed targeting to address tumor antigen heterogeneity. The lead program BCB-276 is advancing a pivotal registrational trial for DIPG.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Updated 6 days ago
Funding
Raised to date
$116.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 1 round
SCUPWC
$116M · Series A
Announced Sep 2026 · from article date
Disclosed cumulative: $116M
RoundDateAmountValuationInvestors
Founders
Product
Problem
Current treatments for central nervous system (CNS) tumors, especially pediatric brain cancers like diffuse intrinsic pontine glioma (DIPG), rely on systemic chemotherapy and radiation, which have limited efficacy and cause significant toxicity. Delivering immunotherapies such as CAR-T cells to the brain is hindered by the blood-brain barrier and the heterogeneous expression of tumor antigens, leading to poor tumor penetration and frequent therapeutic failure.
Solution
BrainChild Bio develops CAR-T cell therapies specifically engineered for CNS tumors. The company administers the cells directly into the cerebroventricular space, bypassing the blood-brain barrier and allowing repeated dosing to maintain a sustained anti-tumor presence. Its platform incorporates multiplexed targeting of several tumor antigens (e.g., EGFR, HER2, B7-H3, IL13Rα2) to reduce antigen-escape, and a PotencyPlus synthetic transgene to enhance cell activity within the immunosuppressive tumor microenvironment. Remote-control mechanisms enable clinicians to modulate cell activity after infusion, improving safety. The approach is designed to provide a potent, localized immunotherapy for both pediatric and adult CNS malignancies without the need for systemic lymphodepleting chemotherapy.
Target Audience
Primary customers are pediatric oncology centers and neuro-oncology programs treating DIPG and other CNS tumors, as well as adult neuro-oncology groups managing glioblastoma and brain metastases.
Features
- Direct intraventricular delivery of CAR-T cells for enhanced tumor access and compartmentalization
- Multiplexed CAR constructs targeting EGFR, HER2, B7-H3, and IL13Rα2 to address antigen heterogeneity
- PotencyPlus synthetic transgene that boosts effector function and counters immunosuppressive microenvironment signals
- Remote-control capability allowing post-infusion regulation of CAR-T cell activity for safety management
- Recursive dosing regimen enabling repeated administrations while minimizing toxicity
- Clinical-stage INDs for four CNS CAR-T products with Phase I safety data
- Lead program BCB-276 targeting B7-H3, universally expressed in DIPG, advancing a pivotal registrational trial (Illuminate, NCT07680439) designed to support a future Biologics License Application
- Next-generation BCB-214 triple-targeting therapy (EGFR x B7-H3 x IL13Rα2) for glioblastoma and diffuse midline glioma